OncoMatch

OncoMatch/Clinical Trials/NCT06592599

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Is NCT06592599 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab for nasopharyngeal carcinoma.

Phase 2RecruitingStanford UniversityNCT06592599Data as of May 2026

Treatment: ToripalimabThe purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage T3-4, ANY N, ANY T, N1-3 (AJCC v8)

Locoregionally advanced EBV positive NPC (T3-4, any N OR any T, N1-3. No M1) per AJCC v 8

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systemic anticancer treatment

Cannot have received: radiation therapy

Lab requirements

Blood counts

ANC ≥ 1,500 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (transfusion/intervention allowed)

Kidney function

Serum creatinine ≤ 1.5 mg/dl or calculated or measured creatinine clearance (CC) ≥ 50 ml/min

Liver function

Total bilirubin ≤ 1.5 x institutional ULN; AST and ALT ≤ 1.5 x institutional ULN

CBC/differential obtained within 21 days prior to day 1 of treatment, with adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.); Adequate hepatic function within 21 days prior to day 1 of treatment, defined as follows: Total bilirubin ≤ 1.5 x institutional ULN; AST and ALT ≤ 1.5 x institutional ULN; Adequate renal function within 21 days prior to day 1 of treatment, defined as follows: Serum creatinine ≤ 1.5 mg/dl or calculated or measured creatinine clearance (CC) ≥ 50 ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Stanford University · Palo Alto, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify